This trial is still recruiting so if you think you are eligible please ask your neurologist to refer you to Cambridge! The aim of this work is to make Alemtuzumab safer, by preventing or reducing the incidence of autoimmune complications of alemtuzumab. It is in everybody’s interest for this to happen!
The purpose of the CAM-THY trial is to try and prevent side effects of alemtuzumab (formerly known as Campath-1h). Although alemtuzumab is an effective treatment of MS, it has side effects; in particular 1 in 3 MSers develop a new autoimmune disease after treatment.
To be eligible for the trial you have to have relapsing-remitting MS, be within ten years of the first symptoms of MS, walk without aids and have had at least 2 clinical attacks or relapse in the previous 2 years. These relapses may have occurred whilst on disease-modifying therapy.
Multiple Sclerosis Research: Research: Alemtuzumab (formerly …
13 Apr 2012
Conversely, mean magnetization transfer ratio was stable in 20 alemtuzumab-treated patients (grey matter: -0.01 pu/year, p = 0.87; white matter: -0.02 pu/year, p = 0.51). The gradient difference in grey matter was 0.25 pu/year …
Multiple Sclerosis Research: Alemtuzumab 5 year follow up
26 Mar 2012
OBJECTIVE: To report the long-term safety and efficacy results from CAMMS223 comparing alemtuzumab with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). What are the long-term effects of …
Multiple Sclerosis Research: Making alemtuzumab or campath …
20 Jan 2012
As you know alemtuzumab or campath-1h has remarkable efficacy in relapsing MS. In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic …
Research: White blood cell depletion and Alemtuzumab
12 Nov 2011
Background: Alemtuzumab is a lymphocyte depleting monoclonal antibody that has marked efficacy for relapsing-remitting multiple sclerosis (MS). One unresolved issue is the duration and significance of the lymphopenia …
Multiple Sclerosis Research: Immune complications of alemtuzumab
03 Oct 2011
The average times from initial and last alemtuzumab exposure to ITP diagnosis were 24.5 and 10.5 months, respectively. Five patients developed severe thrombocytopenia. Four were symptomatic, including fatal intracranial …
Second successful phase III Results for Alemtuzumab in MS
14 Nov 2011
“Alemtuzumab is the most effective DMT in late stage development. The first MS’er was treated with the drug in 1991 by Prof. Alastair Compston in Cambridge; if or when Alemtuzumab becomes available in the UK it will have …
Multiple Sclerosis Research: News: Alemtuzumab $60000 per annum
11 Sep 2011
“Based on its superior efficacy Alemtuzumab should command a premium price. However, the cost will affect its cost-effectiveness and its license in the UK under NICE. Ideally we would like to use Alemtuzumab in early MS; …
Multiple Sclerosis Research: Research: Alemtuzumab treatment of …
09 Sep 2011
This is more of the same (good) news, with regard to Alemtuzumab. This un-controlled and unblinded study indicates that Alemtuzumab (an antibody that kills white blood cells) quells disease activity in MSers who have …
Multiple Sclerosis Research: Alemtuzumab (Lemtrada) misses a …
11 Jul 2011
The second phase three study for alemtuzumab involves patients who have relapsed on Interferon i.e. more active so I wonder whether the results for that trial will be more encouraging. Monday, July 11, 2011 8:04:00 PM …
Multiple Sclerosis Research: Alemtuzumab results – further analysis
18 Jul 2011
“This was not a negative study; Alemtuzumab is still a very promising disease-modifying therapy! The patients in this trial were less active than previously therefore the trial lacked power to detect a difference in relation to …
Multiple Sclerosis Research: Alemtuzumab – risks of developing …
30 Jul 2011
“What is alemtuzumab? You may know the drug as Campath-1h. This is a powerful immuno-modulator that is given as a course of intravenous infusions. It depletes the immune system and allows it to recover. I refer to it as an …
Multiple Sclerosis Research: More on the Alemtuzumab trial
12 Jul 2011
More on the Alemtuzumab trial. The previous post is simply the headline results; we need to wait for the full results that will be presented at the ECTRIMS/ACTRIMS meeting from the 19 – 22 October 2011, in Amsterdam, The …
Genzyme details market potential of Alemtuzumab for MS
17 Jan 2011
Genzyme details market potential of Alemtuzumab for MS. Wow! Let’s hope it is not too expensive for the NHS. Click here to read the press release! Posted by Gavin Giovannoni at 22:55 · Email ThisBlogThis!Share to …
Multiple Sclerosis Research: Genzyme is bought by Sanofi: what will …
16 Feb 2011
Given that there is good evidence that for many patients Alemtuzumab cam provide long-lasting remission, I would hope that neuros wouldn’t encourage patients following Alemtuzumab to start Terilunomide without good …
Multiple Sclerosis Research: Dr. Alasdair Coles: Guest Spot. Long …
14 Feb 2012
Without the persistance of Alasdair Coles and Alastair Compston, I doubt that CAMPATH-1H, (the worlds first humanised monoclonal antibody)/Alemtuzumab/Lemtrada would be on the MS agenda. This drug has told us a …
Multiple Sclerosis Research: Meta-analysis of randomised …
28 Mar 2012
In comparing treatments with interferon beta-1b (250μg), the network analysis revealed that no therapy shows better response for all 3 efficacy outcomes and alemtuzumab, 12 and 24 mg, have better response for 2 of the …
I really hope this trial is a success. Nobody wants to live with a 2nd autoimmune problem
Exactly – in my case it would be my 3rd autoimmune disease – a bit much…
I would rather be walking with a second autoimuune problem than in a wheelchair with only one.
You have to have high IL21 levels to be eligible.
So what is your answer to people suffering with MS anon? I would love to hear your words of wisdom, whilst not agreeing with all on this blog site I appreciate open and frank discussion, but what you're doing is neither.
Regards as always.
"YOU ARE DOING DISABLED HATE"What? If just one newly diagnosed person takes your ranting seriously and becomes disabled as a result, then it's on your head anon. As Andy Clarke put it so well – what would you suggest? Can we lay bets?LDN or CCSVI?
http://youtu.be/UIm8fHxqUAM
Bang goes your theory of a Pharma conspiracy; alemtuzumab is a drug that may cure MS. What do you say to that?
Lynne Heal – Drugs never cure a disease.They merley hush the voice of natures protest and pull down the danger signals she erects along the pathway of transgression. Any poison taken into the system has to be reckoned with later on even though it palliates present symptoms. Pain may disappear,but the patient is left in a worse condition, though unconscious of it at the time. Daniel.H.Kress, M.D
Conspiracy Theorist. Nothing more than a derogatory title used to dismiss a critical thinker
http://en.wikipedia.org/wiki/Alemtuzumab READ ADVERSE SIDE EFFECTS
Bang goes your theory of a Pharma conspiracy; alemtuzumab may cure MS. It is the only drug at present that offers the potential of a cure!
The side effects are worth it if my MS goes into long-term remission.By the way who do you think you are making a call on my behalf? I am able to make up my own mind about what risks I am prepared to take. I know two people with MS who have done fantastically well on campath. I wish I could sign up for this study, but live too far away from Cambridge.
Alemtuzumab has been associated with infusion-related events including hypotension, rigors, fever, shortness of breath, bronchospasm, chills, and/or rash. In post-marketing reports, the following serious infusion-related events were reported: syncope, pulmonary infiltrates, ARDS, respiratory arrest, cardiac arrhythmias, myocardial infarction and cardiac arrest. The cardiac adverse events have resulted in death in some cases.[citation needed] It is also possible that perturbation of suppressor T cell populations by Campath-1H may precipitate autoimmune disease.
Conspiracy Theorist. Nothing more than a derogatory title used to dismiss a critical thinker
"Although alemtuzumab is an effective treatment of MS, it has side effects; in particular 1 in 3 MSers develop a new autoimmune disease after treatment. "I wonder what Sam Trucker makes of this? His/ her pro-DMT stance will seem highly foolish if 'curing' MS is worth it being replaced by a brand new disease. It's illogical, is it not?The right thing to do is to is to figure out how to prevent MS in future generations. Forget the DMTs and trials into progressive MS; let's just start from a clean slate. It's unfortunate that we have MS but let's bite the bullet and shift our focus on newborns. Let's make them vitamin D replete. Let us be the last generation to have lived and died with MS. We've had our moment. Let's accept our fate and live with it rather than drugging ourselves with crap our bodies can't handle. The only reason a MSer will run the risk of taking alemtuzumab is because of desperation. Desperate people are always living in danger. MS can be prevented but it’s dangerous to think that modern toxins will, somehow, cure it.A world free of MS can start right here. Give your kids vitamin D and they will never develop MS.
'Dr Dre' you are free to accept your fate and live with it
Dr Dre, I would rather have thyroid disease; I believe that most people with thyroid disease simply have to take a thyroid supplement every day to replace what is lost. A much better option than MS. If I could trade in my MS for thyroid disease I would be first in the queue. In fact if thyroid disease occurred in 100% of people treated with Campath I would still be first in line. I am not sure if you are a real doctor but if you are you should stop patronizing us. We are all grown up and capable of making our own decisions.
Coming to you from the very centre of Galicia = jayblewes
Yeah? And your point is what? I have MS and I write a blog and I live in the middle of Galicia and I was becoming tired of having to answer as an anon.